Tumor organoids from undifferentiated primary carcinomas to guide treatment choices
Official title: Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Run by Centre Francois Baclesse · NCT06612827 · Data updated 2026-11-12
This project will grow tumor organoids from patients with undifferentiated primary carcinomas to try to predict which treatments might work best for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Centre Francois Baclesse Academic / other |
| Locations | 1 site (Caen) |
| Status | Recruiting |
| Started | March 5, 2025 |
| Main results expected | December 15, 2028 |
| Study ends | December 15, 2032 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT06612827 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histological and immunohistochemical confirmation of undifferentiated primary carcinoma who are eligible for first‑line systemic treatment, have a life expectancy over three months, and can give informed consent.
✕Probably not a fit
People who are pregnant or breastfeeding, legally incapacitated, have a very short life expectancy, or whose tumor samples fail to form organoids are unlikely to gain benefit from the approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project collects tumor and blood samples from adults with histologically confirmed undifferentiated primary carcinoma who are starting first‑line systemic therapy (or have received up to two cycles). Laboratory teams will attempt to establish patient‑derived tumoroids and run functional drug sensitivity tests to compare with patients' clinical responses. The approach aims to create a living biobank and to explore whether tumoroid testing can inform future treatment decisions. The work is conducted at a single center, Centre François Baclesse in Caen, France.
Why it matters
Potential benefit: If successful, the approach could help clinicians choose more effective therapies by testing drugs on a patient’s own tumor cells before giving treatment.
How similar studies have gone: Organoid‑based testing has shown promising ability to predict drug response in several cancer types in early studies, but it is not yet a standard clinical tool.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation * Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered. * Patient with life expectancy greater than 3 months * Patient of legal age * Patient affiliated to a social security scheme * Signature of informed consent prior to any specific study procedure Exclusion Criteria: * Persons deprived of their liberty or under guardianship (including curatorship) * Pregnant or breast-feeding patient
Where it's running
-
Centre François Baclesse
Caen, France Recruiting
Study contacts
- Study coordinator: zoé NEVIERE, Medical Doctor
- Email: z.neviere@baclesse.unicancer.fr
- Phone: 33231455050
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Toripalimab plus carboplatin and docetaxel before surgery for sinonasal cancer
This study tests whether giving toripalimab with carboplatin and docetaxel before surgery helps people with locally advanced sinonasal cancers.
-
Radiation plus tarlatamab for DLL3-expressing tumors
This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.
-
Using pembrolizumab with chemotherapy for advanced sinonasal cancer
This study is testing if adding pembrolizumab to chemotherapy can help people with advanced sinonasal cancer feel better and improve their treatment results.
-
Using enasidenib to treat IDH2-mutated sinonasal and skull base tumors
This study is testing if a new drug called enasidenib can help people with rare nasal or skull base cancers that have a specific mutation and haven't responded to other treatments.
-
Creating a registry for patients with neuroendocrine cervical cancer
This study is creating a database to gather information about patients with neuroendocrine cervical cancer to help improve understanding and treatment of this rare disease.
-
Testing nivolumab with or without ipilimumab for recurrent endometrial cancer
This study is testing if adding ipilimumab to nivolumab can help people with recurrent endometrial cancer live longer and feel better compared to just using nivolumab alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.